Ivermectin has been reported in recent studies, a miracle drug in the treatment of COVID-19 along with doxycycline, but efficacious only at higher doses (12mg/day) and this higher dose is also accompanied with several side effects such as cardiac toxicity. Since, COVID-19 mainly affects the respiratory system especially Lungs, therefore current proposal emphasizes the development of carrier system of Ivermectin targeting lungs directly so that maximum drug reaches the target site. Drug delivery system composed of combination of both drugs helps in reducing the dose and thereby dose related toxicity issue can be resolved. To reduce the dose related toxicity and increase the efficacy, combination of Ivermectin and doxycycline carrier system in micron size range can be helpful in the treatment of COVID-19. For this, a combination of polymers PLGA and PEG has been selected. Both these polymers can be conjugated chemically in the presence of EDC/NHS. PLGA will be helpful in showing better penetration from the epithelial layers and will show high drug bioavailability. The mechanistic approaches will be evaluated and validated using in silico and in vivo biological interventions. In conclusion, Combination of 2 drugs: Ivermectin and doxcycline can be used for the treatment of COVID 2019 via lung targeting.
Winner of Novate+2021
Ms. Malkiet Kaur
Email – firstname.lastname@example.org
Mobile – 6280002664